Novartis Announces Positive Results for Fabhalta
Novartis, a leading innovative medicines company, has announced that its Fabhalta (iptacopan) has met the primary endpoint in a Phase III trial, demonstrating its ability to slow kidney function decline in patients with IgA nephropathy (IgAN).
As a company, Novartis aims to "reimagine medicine" to improve and extend people's lives, empowering patients, healthcare professionals, and societies in the face of serious disease.
- Novartis medicines reach 296 million people worldwide.
- The company provides various resources, including clinical trial recruiting, managed access programs, and funding opportunities for patient organizations.
- Novartis also offers resources for physicians and healthcare professionals, such as grant funding, congresses, and country-level information.
Our goal is to improve and extend people's lives so that patients, healthcare professionals and societies are empowered in the face of serious disease.
Novartis is committed to making a positive impact on the world by providing access to innovative medicines, protecting the environment, and upholding high ethical standards, as outlined in the Novartis in Society Integrated Report.
Author's summary: Novartis Fabhalta slows kidney decline in IgA nephropathy patients.